Stocktoria

Candel Therapeutics, Inc. CADL

Nasdaq · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2021-07-27

Candel Therapeutics, Inc. statistics & valuation

Market cap$717.3M
P / B13.8×
Return on equity-73.5%
Return on capital-41.5%

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Gross margin (%)
202020212022202320242025
Operating margin (%)
-11048.00% -20580.80% -27777.60% 202020212022202320242025
Return on equity (%)
-56.30% -39.40% -297.70% -83.20% -73.50% 202020212022202320242025
Shares outstanding
11.6M 28.7M 28.9M 29.1M 46.8M 54.9M 202020212022202320242025
Net debt ($)
-$34.6M -$82.1M -$23.8M -$100.9M 202020212022202320242025
Share buybacks ($)
202020212022202320242025
Return on assets (%)
-46.20% -40.50% -24.20% -92.10% -51.60% -30.50% 202020212022202320242025
Free cash flow margin (%)
-8437.60% -19242.40% -26172.80% 202020212022202320242025
Debt / equity (×)
0.01× 0.91× 0.03× 202020212022202320242025
EPS ($)
-$1.91 -$0.65 -$1.31 -$1.74 -$0.72 202020212022202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023FY2022FY2021FY2020
Operating margin———-27777.6%-20580.8%-11048.0%
Net margin———-15035.2%-28899.2%-14144.0%
FCF margin———-26172.8%-19242.4%-8437.6%
Return on assets-30.5%-51.6%-92.1%-24.2%-40.5%-46.2%
Return on equity-73.5%-83.2%-297.7%-39.4%-56.3%75.0%
Debt / equity—0.03×0.91×—0.01×-0.02×
Current ratio13.492.772.5912.8115.847.46

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.